Clinical Trial | By TM Nazif, J Moses, REFLECT II Trial Investigators et al.
OBJECTIVES - The REFLECT II (Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Implantation) trial was designed to investigate the safety and efficacy of the TriGUARD 3 (TG3) cerebral embolic protection in patients undergoing transcatheter aortic valve replacement. BACKGROUND - Cerebral embolization occurs frequently following transcatheter ...
Original Research | By SS Dhruva, JS Ross, BJ Mortazavi et al.
Original Research | By JP Ferreira, Z Lamiral, G Bakris et al.
BACKGROUND - Red blood cell distribution width (RDW) is a measure of size variability in the red blood cell population (anisocytosis). Increased RDW may arise from any condition that affects erythropoiesis or the survival of erythrocytes. RDW has been associated with poor prognosis in patients with type 2 diabetes (T2D). Whether RDW is a risk marker for adverse cardiovascular outcomes or also a marker of non‐cardiovascular health c...
Review Article | By G Muntané-Carol , F Philippon , I Nault et al.
Transcatheter aortic valve replacement (TAVR) has changed the treatment of patients with severe aortic stenosis. However, the occurrence of conduction disturbances has not decreased significantly over time and remains the main drawback of the procedure. In addition, new-onset atrial fibrillation is the most frequent tachyarrhythmia during the hospitalization period and is associated with worse clinical outcomes. However, little is known r...
Original Research | By GA Figtree, ST Vernon, N Hadziosmanovic et al.
BACKGROUND - In cardiovascular disease, prevention strategies targeting standard modifiable cardiovascular risk factors (SMuRFs; hypertension, diabetes, hypercholesterolaemia, and smoking) are crucial; however, myocardial infarction in the absence of SMuRFs is not infrequent. The outcomes of individuals without SMuRFs are not well known. METHODS - We retrospectively analysed adult patients ...
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Guideline | By National Institue for Health and Care Excellence